Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 20/20 | 0.84 |
| ▸ | BRDT | Q58F21 | 10/20 | 0.72 |
| ▸ | DNER | Q8NFT8 | 1/20 | 0.60 |
| ▸ | BRD2 | P25440 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3205819 | 0.92 | BRD4 (0.83) | BRD4BRDTDNERBRD2 | |
| SCHEMBL3215449 | 0.92 | BRD4 (0.71) | BRD4BRDTDNERBRD2 | |
| SCHEMBL3214233 | 0.92 | BRD4 (0.71) | BRD4BRDTBRD2 | |
| SCHEMBL3196656 | 0.92 | BRD4 (0.71) | BRD4BRDTBRD2 | |
| SCHEMBL17839803 | 0.91 | BRD4 (0.85) | BRD4BRDTDNERBRD2 | |
| SCHEMBL13028865 | 0.91 | BRD4 (1.00) | BRD4BRDTBRD2 | |
| SCHEMBL3211359 | 0.91 | BRD4 (0.70) | BRD4BRDT | |
| SCHEMBL3201388 | 0.91 | BRD4 (0.70) | BRD4BRDTDNERBRD2 | |
| SCHEMBL3204942 | 0.90 | BRD4 (0.70) | BRD4BRDTDNERBRD2 | |
| SCHEMBL3197992 | 0.90 | BRD4 (0.84) | BRD4BRDTBRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1887008-B1 | THIENOTRIAZOLODIAZEPINE COMPOUND AND A MEDICINAL USE THEREOF | MITSUBISHI TANABE PHARMA CORP (JP) | 2021-04-21 | — | — | EP | claimed |
| EP-2863923-B1 | THIENOTRIAZOLODIAZEPINE COMPOUNDS FOR THE TREATMENT OF LYMPHOMAS | ONCOETHIX GMBH (CH) | 2019-05-08 | — | — | EP | claimed |
| EP-3185871-A1 | METHODS OF TREATING ACUTE MYELOID LEUKEMIA OR ACUTE LYMPHOID LEUKEMIA USING PHARMACEUTICAL COMPOSITIONS CONTAINING THIENOTRIAZOLODIAZEPINE COMPOUNDS | Oncoethix GmbH (CH) | 2017-07-05 | — | — | EP | claimed |
| US-20170157141-A1 | METHOD OF TREATING LEUKEMIA USING PHARMACEUTICAL FORMULATION CONTAINING THIENOTRIAZOLODIAZEPINE COMPOUNDS | ONCOETHIX GMBH (CH) | 2017-06-08 | — | — | US | claimed |
| EP-3154549-A1 | METHOD OF TREATING NON-SMALL CELL LUNG CANCER AND/OR SMALL CELL LUNG CANCER USING THIENOTRIAZOLODIAZEPINE COMPOUNDS | Oncoethix GmbH (CH) | 2017-04-19 | — | — | EP | claimed |
| EP-3137085-A1 | METHOD OF TREATING ACUTE MYELOID LEUKEMIA AND/OR ACUTE LYMPHOBLASTIC LEUKEMIA USING THIENOTRIAZOLODIAZEPINE COMPOUNDS | Oncoethix GmbH (CH) | 2017-03-08 | — | — | EP | claimed |
| US-20160375032-A1 | METHOD OF TREATING NON-SMALL-CELL LUNG CANCER USING PHARMACEUTICAL FORMULATION CONTAINING THIENOTRIAZOLODIAZEPINE COMPOUNDS | ONCOETHIX GMBH (CH) | 2016-12-29 | — | — | US | claimed |
| EP-3074019-A1 | METHOD OF TREATING NON-SMALL-CELL LUNG CANCER USING PHARMACEUTICAL FORMULATION CONTAINING THIENOTRIAZOLODIAZEPINE COMPOUNDS | Oncoethix GmbH (CH) | 2016-10-05 | — | — | EP | claimed |
| EP-3074018-A1 | METHOD OF TREATING LEUKEMIA USING PHARMACEUTICAL FORMULATION CONTAINING THIENOTRIAZOLODIAZEPINE COMPOUNDS | Oncoethix GmbH (CH) | 2016-10-05 | — | — | EP | claimed |
| US-20160158246-A1 | METHOD OF TREATING DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) USING A BET-BROMODOMAIN INHIBITOR | ONCOETHIX GMBH (CH) | 2016-06-09 | — | — | US | claimed |
| WO-2015078928-A1 | METHOD OF TREATING NON-SMALL-CELL LUNG CANCER USING PHARMACEUTICAL FORMULATION CONTAINING THIENOTRIAZOLODIAZEPINE COMPOUNDS | ONCOETHIX SA (CH) | 2015-06-04 | — | — | WO | claimed |
| EP-2863923-A1 | METHOD OF TREATING LYMPHOMA USING THIENOTRIAZOLODIAZEPINE COMPOUNDS | Oncoethix SA (CH) | 2015-04-29 | — | — | EP | claimed |
| WO-2015018520-A1 | A BET-BRD INHIBITOR REPRESENTS A NOVEL AGENT FOR ALK POSITIVE ANAPLASTIC LARGE CELL LYMPHOMA | ONCOETHIX SA (CH) | 2015-02-12 | — | — | WO | claimed |
| US-20140107107-A1 | PHARMACEUTICAL FORMULATION CONTAINING THIENOTRIAZOLODIAZEPINE COMPOUNDS | ONCOETHIX GMBH (CH) | 2014-04-17 | — | — | US | claimed |
| WO-2014001356-A1 | METHOD OF TREATING LYMPHOMA USING THIENOTRIAZOLODIAZEPINE COMPOUNDS | ONCOETHIX SA (CH) | 2014-01-03 | — | — | WO | claimed |
| US-8476260-B2 | Antitumor agent | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-07-02 | — | — | US | claimed |
| US-20100286127-A1 | ANTITUMOR AGENT | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-11-11 | — | — | US | claimed |
| EP-2239264-A1 | ANTITUMOR AGENT | Mitsubishi Tanabe Pharma Corporation (JP) | 2010-10-13 | — | — | EP | claimed |
| US-20100041643-A1 | THIENOTRIAZOLODIAZEPINE COMPOUND AND MEDICINAL USE THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-02-18 | — | — | US | claimed |
| EP-1887008-A1 | THIENOTRIAZOLODIAZEPINE COMPOUND AND A MEDICINAL USE THEREOF | Mitsubishi Tanabe Pharma Corporation (JP) | 2008-02-13 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160158246-A1 | METHOD OF TREATING DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) USING A BET-BROMODOMAIN INHIBITOR | BRD4, BRD7, BCL6 | BRD4 1/4885BRDT 14/4885DNER 1306/4885 |
| US-20170157141-A1 | METHOD OF TREATING LEUKEMIA USING PHARMACEUTICAL FORMULATION CONTAINING THIENOTRIAZOLODIAZEPINE COMPOUNDS | CCR10, HRH4, H1-10 | BRD4 22/4885BRDT 499/4885DNER 4327/4885 |
| US-20140107107-A1 | PHARMACEUTICAL FORMULATION CONTAINING THIENOTRIAZOLODIAZEPINE COMPOUNDS | HRH4, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HTR3D | BRD4 97/4885BRDT 1044/4885DNER 4847/4885 |
| US-20100286127-A1 | ANTITUMOR AGENT | BRDT, HDAC1, BRPF3 | BRD4 4/4885BRDT 1/4885DNER 3822/4885 |
| US-20160375032-A1 | METHOD OF TREATING NON-SMALL-CELL LUNG CANCER USING PHARMACEUTICAL FORMULATION CONTAINING THIENOTRIAZOLODIAZEPINE COMPOUNDS | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HRH4, CCR10 | BRD4 20/4885BRDT 198/4885DNER 2991/4885 |
| US-20100041643-A1 | THIENOTRIAZOLODIAZEPINE COMPOUND AND MEDICINAL USE THEREOF | ICOS, CD4, CD2 | BRD4 265/4885BRDT 159/4885DNER 3109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.